PMV Pharmaceuticals, Inc.
PMVPNasdaqCIK 1699382HealthcareFiscal year ends Dec 31
Reports and events: 84 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0513:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-413254 |
| 2026-09-0222:23 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-378838 |
| 2026-08-3120:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-376723 |
| 2026-08-1412:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-350448 |
| 2026-08-1412:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-350445 |
| 2026-06-0512:10 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-258466 |
| 2026-05-1212:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-218227 |
| 2026-05-1212:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218225 |
| 2026-04-2212:01 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001140361-26-016038 |
| 2026-03-0613:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-095094 |
| 2026-03-0613:01 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-095014 |
| 2026-03-0402:12 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-26-000231 |
| 2025-11-1213:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-276003 |
| 2025-11-1213:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-276000 |
| 2025-10-2721:12 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-25-000926 |
| 2025-09-1016:04 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-199857 |
| 2025-08-0712:00 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104588 |
| 2025-08-0712:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104587 |
| 2025-06-0913:02 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-137497 |
| 2025-05-0912:00 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-067513 |
| 2025-05-0912:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-067511 |
| 2025-04-2513:00 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0001140361-25-015610 |
| 2025-03-0313:45 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-030414 |
| 2025-03-0313:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-030407 |
| 2024-11-0713:00 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122817 |
| 2024-11-0713:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122816 |
| 2024-08-0812:00 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093343 |
| 2024-08-0812:00 ET | 8-K | 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093345 |
| 2024-06-0712:32 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-156745 |
| 2024-05-0912:00 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056295 |
| 2024-05-0912:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056294 |
| 2024-04-2412:00 ET | DEF 14A | Proxy statementPeriod 2024-06-06 | 0001140361-24-021596 |
| 2024-02-2921:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-023062 |
| 2024-02-2921:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-023058 |
| 2024-01-1821:02 ET | 8-K | 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-010177 |
| 2024-01-0521:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003348 |
| 2023-11-0913:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061551 |
| 2023-11-0913:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-061552 |
| 2023-10-1221:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-255083 |
| 2023-10-1120:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-254135 |
| 2023-08-2320:56 ET | SC 13D/A | Ownership report, active investor, amended | 0000947871-23-000902 |
| 2023-08-0912:01 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-040153 |
| 2023-08-0912:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-040151 |
| 2023-06-0912:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-164011 |
| 2023-05-1012:02 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-020100 |
| 2023-05-1012:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-020097 |
| 2023-04-2812:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-23-124381 |
| 2023-04-2812:01 ET | DEF 14A | Proxy statementPeriod 2023-06-08 | 0001140361-23-021220 |
| 2023-03-0113:02 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-005345 |
| 2023-03-0113:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-005343 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.